<!DOCTYPE html>
<html lang="en">

<head>
  <title>ANS | The Peripheral Brain</title>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">

  <script src='https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.2/MathJax.js?config=TeX-MML-AM_CHTML'></script>

  <link rel="stylesheet" href="/peripheral_brain/css/main.css" />
  <link rel="stylesheet" href="/peripheral_brain/css/mobile.css" />
  <link rel="stylesheet" href="/peripheral_brain/css/buttons.css" />

  
    <link rel="stylesheet" href="/peripheral_brain/css/diseases.css">
  


  <link href="https://fonts.googleapis.com/css?family=Open+Sans" rel="stylesheet">
  <link href="https://fonts.googleapis.com/css?family=Roboto+Slab" rel="stylesheet">
  <link href="https://fonts.googleapis.com/css?family=Roboto+Mono" rel="stylesheet">
  <link href="https://fonts.googleapis.com/css?family=Roboto+Condensed" rel="stylesheet">


  <link rel="apple-touch-icon" sizes="180x180" href="/peripheral_brain/favicons/apple-touch-icon.png">
  <link rel="icon" type="image/png" sizes="32x32" href="/peripheral_brain/favicons/favicon-32x32.png">
  <link rel="icon" type="image/png" sizes="16x16" href="/peripheral_brain/favicons/favicon-16x16.png">
  <link rel="manifest" href="/peripheral_brain/favicons/site.webmanifest">
  <link rel="mask-icon" href="/peripheral_brain/favicons/safari-pinned-tab.svg" color="#465c8b">
  <link rel="shortcut icon" href="/peripheral_brain/favicons/favicon.ico">
  <meta name="apple-mobile-web-app-title" content="Peripheral Brain">
  <meta name="application-name" content="Peripheral Brain">
  <meta name="msapplication-TileColor" content="#da532c">
  <meta name="msapplication-config" content="/peripheral_brain/favicons/browserconfig.xml">
  <meta name="theme-color" content="#cdcdcd">


  
  
</head>


<body class="body">
<header>
  <nav>
    <!-- <a href="/peripheral_brain/home.html"><img src="/peripheral_brain/images/logo_1000x1000.png" alt="Logo"> -->
      <ul class="nav-links">
        <li><a href="/peripheral_brain/home.html">Home</a></li>
        <li><a href="/peripheral_brain/disease_list.html">Diseases and Drugs</a></li>
        <li><a href="/peripheral_brain/firstFive">TF5M</a></li>
        <li><a href="/peripheral_brain/lab_values">Lab Values</a></li>
        <li><a href="/peripheral_brain/formulas">Formulas</a></li>
        <li><a href="/peripheral_brain/calculators.html">Calculators</a></li>
        <li><a href="/peripheral_brain/search.html">Search</a></li>
      </ul>
  </nav>
</header>


<h1 class="title">ANS</h1>

<div class="contents">

  <div class="toc">
    
      <ul>
  <li><a href="#ans-overview">ANS Overview</a>
    <ul>
      <li><a href="#ans-anatomy">ANS Anatomy</a></li>
      <li><a href="#unique-ans-innervations">Unique ANS Innervations</a></li>
      <li><a href="#ans-receptors">ANS Receptors</a></li>
    </ul>
  </li>
  <li><a href="#sympathomimetics">Sympathomimetics</a>
    <ul>
      <li><a href="#ses">SEs</a></li>
    </ul>
  </li>
  <li><a href="#sympatholytics">Sympatholytics</a>
    <ul>
      <li><a href="#α-blockers">α-Blockers</a>
        <ul>
          <li><a href="#ses-α1-blockade">SEs α<sub>1</sub> Blockade</a></li>
        </ul>
      </li>
      <li><a href="#β-blockers">β-Blockers</a>
        <ul>
          <li><a href="#ses-1">SEs</a></li>
        </ul>
      </li>
      <li><a href="#catecholamine-depleters">Catecholamine Depleters</a></li>
    </ul>
  </li>
  <li><a href="#cholinergics">Cholinergics</a>
    <ul>
      <li><a href="#cholinergic-toxidrome">Cholinergic Toxidrome</a></li>
      <li><a href="#direct-cholinergic-agents">Direct Cholinergic Agents</a></li>
      <li><a href="#cholinesterase-inhibitors">Cholinesterase Inhibitors</a>
        <ul>
          <li><a href="#treatment-of-anticholinesterase-inhibitor-poisoning">Treatment of Anticholinesterase Inhibitor Poisoning</a></li>
        </ul>
      </li>
    </ul>
  </li>
  <li><a href="#anticholinergics">Anticholinergics</a>
    <ul>
      <li><a href="#paralytics">Paralytics</a></li>
    </ul>
  </li>
</ul>

    
  </div>

  <div class="content">
    <h1 id="ans-overview">ANS Overview</h1>

<h2 id="ans-anatomy">ANS Anatomy</h2>

<ul>
  <li>ANS is subdivided into sympathetic and parasympathetic neurons</li>
  <li>Sympathetic innervations branch from T1-L2 and the sympathetic ganglia lie along both sides of the spinal cord (but the ganglia are higher and lower then the branches innervating them)</li>
  <li>Parasympathetic innervations branch from the brainstem and sacral spine</li>
  <li>All preganglionic neurons utilize acetylcholine</li>
  <li>Sympathetic presynaptic neurons are short, meeting the ganglia near the spinal cord, and have long post-ganglionic neurons. Post-ganglionic neurons from a single ganglion can innervate multiple neurons, and utilize NE as their neurotransmitter</li>
  <li>Parasympathetic preganglionic neurons are long, meeting the ganglia which rest near their target organ. The postganglionic neurons are short, innervate a single organ, and utilize ACh.</li>
</ul>

<h2 id="unique-ans-innervations">Unique ANS Innervations</h2>

<ul>
  <li>Sweat Glands
    <ul>
      <li>Post-ganglionic <strong>sympathetic</strong> neurons secrete ACh to stimulate sweating</li>
    </ul>
  </li>
  <li>Kidneys
    <ul>
      <li>Sympathetic innervations of renal vasculature secrete <strong>dopamine</strong> to cause vasodilation</li>
    </ul>
  </li>
  <li>Adrenal Glands
    <ul>
      <li>The adrenal glands act as sympathetic ganglion, i.e. preganglionic neurons release ACh onto nicotinic receptors in the gland, leading to epinephrine and norepinephrine release into systemic circulation</li>
    </ul>
  </li>
</ul>

<h2 id="ans-receptors">ANS Receptors</h2>

<table>
  <thead>
    <tr>
      <th>Receptor</th>
      <th>Signaling Pathway</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Nicotinic Receptor</td>
      <td>Na Influx</td>
    </tr>
    <tr>
      <td>M<sub>1,3,5</sub></td>
      <td>G<sub>q</sub></td>
    </tr>
    <tr>
      <td>M<sub>2,4</sub></td>
      <td>G<sub>I/O</sub></td>
    </tr>
    <tr>
      <td>α<sub>1</sub></td>
      <td>G<sub>q</sub></td>
    </tr>
    <tr>
      <td>α<sub>2</sub></td>
      <td>G<sub>i</sub></td>
    </tr>
    <tr>
      <td>β</td>
      <td>G<sub>S</sub></td>
    </tr>
  </tbody>
</table>

<table>
  <thead>
    <tr>
      <th>Physiologic Parameter</th>
      <th>Symp. Receptor</th>
      <th>Effect</th>
      <th>Para. Receptor</th>
      <th>Effect</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Chronotropy</td>
      <td>β<sub>1&gt;2</sub></td>
      <td>Increase</td>
      <td>M<sub>2</sub></td>
      <td>Decrease</td>
    </tr>
    <tr>
      <td>Inotropy</td>
      <td>β<sub>1&gt;2</sub></td>
      <td>Increase</td>
      <td>M<sub>2</sub></td>
      <td>Decrease</td>
    </tr>
    <tr>
      <td>Arteries (most)</td>
      <td>α<sub>1</sub></td>
      <td>Constrict</td>
      <td> </td>
      <td> </td>
    </tr>
    <tr>
      <td>Veins</td>
      <td>α<sub>1,2</sub></td>
      <td>Constrict</td>
      <td> </td>
      <td> </td>
    </tr>
    <tr>
      <td>Skeletal Muscle Vessels</td>
      <td>β<sub>2</sub></td>
      <td>Dilate</td>
      <td> </td>
      <td> </td>
    </tr>
    <tr>
      <td>Endothelium</td>
      <td> </td>
      <td> </td>
      <td>M<sub>3</sub></td>
      <td>Release EDRF (minimal vascular relaxation)</td>
    </tr>
    <tr>
      <td>Bronchioles</td>
      <td>β<sub>2</sub></td>
      <td>Dilate</td>
      <td>M<sub>3&gt;2</sub></td>
      <td>Constrict</td>
    </tr>
    <tr>
      <td>Bladder Wall</td>
      <td>β<sub>2</sub></td>
      <td>Relax</td>
      <td>M<sub>3</sub></td>
      <td>Constrict</td>
    </tr>
    <tr>
      <td>Ureter</td>
      <td>α<sub>1</sub></td>
      <td>Contract</td>
      <td>M<sub>3</sub></td>
      <td>Relax</td>
    </tr>
    <tr>
      <td>Urinary Sphincter</td>
      <td>α<sub>1</sub></td>
      <td>Contract</td>
      <td>M<sub>3</sub></td>
      <td>Relax</td>
    </tr>
    <tr>
      <td>Uterus</td>
      <td>β<sub>2</sub><br />α<sub>1</sub></td>
      <td>Relax<br />Contract</td>
      <td>M<sub>3</sub></td>
      <td>Variable</td>
    </tr>
    <tr>
      <td>Penis/Vas Deferens</td>
      <td>α<sub>1</sub></td>
      <td>Ejaculation</td>
      <td>M<sub>3</sub></td>
      <td>Erection</td>
    </tr>
    <tr>
      <td>Salivary Glands</td>
      <td>α<sub>1</sub></td>
      <td>Increase Secretion</td>
      <td>M<sub>3</sub></td>
      <td>Increase Secretion</td>
    </tr>
    <tr>
      <td>GI Walls</td>
      <td>α<sub>2</sub>, β<sub>2</sub></td>
      <td>Relax</td>
      <td>M<sub>2,3</sub></td>
      <td>Contraction</td>
    </tr>
    <tr>
      <td>GI Sphincters</td>
      <td>α<sub>1</sub></td>
      <td>Contract</td>
      <td>M<sub>2,3</sub></td>
      <td>Relaxation</td>
    </tr>
    <tr>
      <td>GI Secretions</td>
      <td>α<sub>2</sub></td>
      <td>Inhibit Secretion</td>
      <td>M<sub>2,3</sub></td>
      <td>Increase Secretion</td>
    </tr>
    <tr>
      <td>Skin Follicle Muscles</td>
      <td>α<sub>1</sub></td>
      <td>Contraction and Piloerection</td>
      <td> </td>
      <td> </td>
    </tr>
    <tr>
      <td>Thermoregulatory Sweating</td>
      <td>M<sub>3</sub></td>
      <td>Increase Secretion</td>
      <td> </td>
      <td> </td>
    </tr>
    <tr>
      <td>Stress (Apocrine) Sweating</td>
      <td>α<sub>1</sub></td>
      <td>Increase Secretion</td>
      <td> </td>
      <td> </td>
    </tr>
    <tr>
      <td>Iris Radial Muscle</td>
      <td>α<sub>1</sub></td>
      <td>Contract</td>
      <td> </td>
      <td> </td>
    </tr>
    <tr>
      <td>Iris Circular Muscle</td>
      <td> </td>
      <td> </td>
      <td>M<sub>3</sub></td>
      <td>Contract</td>
    </tr>
    <tr>
      <td>Ciliary Muscle</td>
      <td>β<sub>2</sub></td>
      <td>Minor Relaxation</td>
      <td>M<sub>3</sub></td>
      <td>Contract</td>
    </tr>
    <tr>
      <td>Ciliary Epithelium</td>
      <td>β<sub>2</sub></td>
      <td>Increase Aqueous Humor Secretion</td>
      <td> </td>
      <td> </td>
    </tr>
    <tr>
      <td>Liver</td>
      <td>α<sub>1</sub>, β<sub>2</sub></td>
      <td>Gluconeogenesis and Glycogenolysis</td>
      <td> </td>
      <td> </td>
    </tr>
    <tr>
      <td>Adipose Tissue</td>
      <td>α<sub>1</sub>, β<sub>1,2,3 (if it exists)</sub></td>
      <td>Lipolysis</td>
      <td> </td>
      <td> </td>
    </tr>
    <tr>
      <td>Kidney</td>
      <td>β<sub>1</sub></td>
      <td>Increase Renin Release</td>
      <td> </td>
      <td> </td>
    </tr>
    <tr>
      <td>Pancreas</td>
      <td>α<sub>2</sub></td>
      <td>Decrease insulin release</td>
      <td> </td>
      <td> </td>
    </tr>
  </tbody>
</table>

<h1 id="sympathomimetics">Sympathomimetics</h1>

<table>
  <thead>
    <tr>
      <th>Drug</th>
      <th>Receptor Specificity</th>
      <th>Notes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Norepinephrine</td>
      <td>α, β</td>
      <td>Inopressor</td>
    </tr>
    <tr>
      <td>Epinephrine</td>
      <td>α, β</td>
      <td>Inopressor, anaphylaxis, cardiac arrest, vasoconstrictor</td>
    </tr>
    <tr>
      <td>Phenylephrine</td>
      <td>α<sub>1</sub></td>
      <td>Mydriasis w/o cycloplegia, push-dose pressor, decongestant</td>
    </tr>
    <tr>
      <td>Naphazoline<br />Tetrahydrozoline<br />Oxymetazoline</td>
      <td>α<sub>1</sub> partial agonist</td>
      <td>Nasal and ophthalmic decongestant / vasoconstrictor<br />Tachyphylaxis</td>
    </tr>
    <tr>
      <td>Methyldopa (prodrug)<br />Clonidine<br />Guanabenz<br />Guanfacine<br />Apraclonidine<br />Tizanidine</td>
      <td>α<sub>2</sub></td>
      <td>HTN, vasomotor menopausal SSx, and many psychiatric uses<br />Inhibit preganglionic innervation of heart, kidney, and vascular α<sub>1</sub> causing bradycardia, decreased renin release, and inhibition of vasoconstriction<br />Apraclonidine is used primarily for glaucoma<br />Tizanidine is primarily used for muscle spasticity</td>
    </tr>
    <tr>
      <td>Isoproteronol</td>
      <td>β</td>
      <td>Used in Asthma, COPD, and as an inotrope</td>
    </tr>
    <tr>
      <td>Metaproterenol<br />Terbutaline<br />Albuterol<br />Salmeterol<br />Formoterol<br />-erols</td>
      <td>β<sub>2</sub></td>
      <td>Bronchodilator<br />Terbutaline can be used as a tocolytic in premature labor</td>
    </tr>
    <tr>
      <td>Dobutamine</td>
      <td>β</td>
      <td>Dopamine derivative<br /><strong>Inotrope w/ little chronotropic activity</strong> due to enantiomers’ competing chronotropic actions</td>
    </tr>
    <tr>
      <td>Amphetamines</td>
      <td>Inhibition of VMAT leading to reversal of DAT, NET, and SERT</td>
      <td>Indirect sympathomimetic<br />Used in ADHD, narcolepsy, obesity, and ephedrine and pseudoephedrine are decongestants<br /><strong>Ephedrine is unique and is a direct adrenergic agonist</strong></td>
    </tr>
    <tr>
      <td>Cocaine</td>
      <td>NERT, DAT, and SERT Inhibitor</td>
      <td> </td>
    </tr>
    <tr>
      <td>Phenelzine<br />Selegiline</td>
      <td>MAOIs</td>
      <td>NE, Epi, Phenylephrine are sensitive</td>
    </tr>
  </tbody>
</table>

<h2 id="ses">SEs</h2>

<ul>
  <li>α<sub>2</sub> Agonists
    <ul>
      <li>Dry Mouth</li>
      <li>Increased aldosterone release</li>
      <li>Sedation</li>
      <li>Rebound Tachycardia</li>
    </ul>
  </li>
</ul>

<h1 id="sympatholytics">Sympatholytics</h1>

<h2 id="α-blockers">α-Blockers</h2>

<table>
  <thead>
    <tr>
      <th>Drug</th>
      <th>Receptor Selectivity</th>
      <th>Notes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Phenoxybenzamine</td>
      <td>α<sub>1,2</sub>, Histamine, ACh, 5HT (Irreversible)</td>
      <td>Useful in HTN crisis and pheochromocytomas</td>
    </tr>
    <tr>
      <td>Phentolamine</td>
      <td>α<sub>1,2</sub></td>
      <td>IV only, useful in HTN crisis and pheochromocytomas</td>
    </tr>
    <tr>
      <td>Prazosin</td>
      <td>α<sub>1</sub></td>
      <td>BPH, HTN<br />t<sub>1/2</sub>: 3hr</td>
    </tr>
    <tr>
      <td>Terazosin</td>
      <td>α<sub>1</sub></td>
      <td>BPH, HTN<br />t<sub>1/2</sub>: 12hr</td>
    </tr>
    <tr>
      <td>Doxazosin</td>
      <td>α<sub>1</sub></td>
      <td>BPH, HTN<br />t<sub>1/2</sub>: 20hr</td>
    </tr>
  </tbody>
</table>

<h3 id="ses-α1-blockade">SEs α<sub>1</sub> Blockade</h3>

<ul>
  <li>Orthostatic Hypotension</li>
  <li>Inhibition of Ejaculation</li>
  <li>Congestion</li>
  <li>Reflex Tachycardia</li>
</ul>

<h2 id="β-blockers">β-Blockers</h2>

<table>
  <thead>
    <tr>
      <th>Drug</th>
      <th>Receptor Selectivity</th>
      <th>ISA</th>
      <th>Usual Maintenance Dose</th>
      <th>Notes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Acebutolol</td>
      <td>β<sub>1</sub></td>
      <td>+</td>
      <td>200-600mg BID</td>
      <td> </td>
    </tr>
    <tr>
      <td>Atenolol</td>
      <td>β<sub>1</sub></td>
      <td>0</td>
      <td>50-100mg QD</td>
      <td> </td>
    </tr>
    <tr>
      <td>Betaxolol</td>
      <td>β<sub>1</sub></td>
      <td>0</td>
      <td>10-20mg QD</td>
      <td> </td>
    </tr>
    <tr>
      <td>Bisoprolol</td>
      <td>β<sub>1</sub></td>
      <td>0</td>
      <td>5-10mg QD</td>
      <td>Approved for CHF</td>
    </tr>
    <tr>
      <td>Carteolol</td>
      <td>β<sub>1</sub>, β<sub>2</sub></td>
      <td>++</td>
      <td>2.5-10mg QD</td>
      <td>Partial Agonist</td>
    </tr>
    <tr>
      <td>Carvedilol</td>
      <td>β<sub>1</sub>, β<sub>2</sub>, α<sub>1</sub></td>
      <td>0</td>
      <td>25-50mg BID</td>
      <td>Approved for CHF</td>
    </tr>
    <tr>
      <td>Esmolol</td>
      <td>β<sub>1</sub></td>
      <td>0</td>
      <td>HTN Emergency: 500-1000mcg/kg over 1min<br />50-200mcg/kg/min</td>
      <td>IV Only<br />t<sub>1/2</sub>: 9min<br />Incompatible w/ Bicarb<br />Useful for rapid HR and BP control as a drip</td>
    </tr>
    <tr>
      <td>Labetalol</td>
      <td>β<sub>1</sub>, β<sub>2</sub>, α<sub>1</sub></td>
      <td>0</td>
      <td>200-400mg BID</td>
      <td>Enantiomers possess different properties</td>
    </tr>
    <tr>
      <td>Metoprolol  Tartrate</td>
      <td>β<sub>1</sub></td>
      <td>0</td>
      <td>50-100mg BID</td>
      <td> </td>
    </tr>
    <tr>
      <td>Metoprolol Succinate</td>
      <td>β<sub>1</sub></td>
      <td>0</td>
      <td>100-200mg QD</td>
      <td>Approved for CHF</td>
    </tr>
    <tr>
      <td>Nebivolol</td>
      <td>β<sub>1</sub></td>
      <td>0</td>
      <td>5-40mg QD</td>
      <td>Increases NO production</td>
    </tr>
    <tr>
      <td>Nadolol</td>
      <td>β<sub>1</sub>, β<sub>2</sub></td>
      <td>0</td>
      <td>40-80mg QD</td>
      <td>t<sub>1/2</sub>: 20hr</td>
    </tr>
    <tr>
      <td>Penbutolol</td>
      <td>β<sub>1</sub>, β<sub>2</sub></td>
      <td>+</td>
      <td>20mg QD</td>
      <td> </td>
    </tr>
    <tr>
      <td>Pindolol</td>
      <td>β<sub>1</sub>, β<sub>2</sub></td>
      <td>+++</td>
      <td>5-20mg BID</td>
      <td>Partial Agonist</td>
    </tr>
    <tr>
      <td>Propranolol</td>
      <td>β<sub>1</sub>, β<sub>2</sub></td>
      <td>0</td>
      <td>Variable</td>
      <td>Lipophilic<br />Reduces Renin Release</td>
    </tr>
    <tr>
      <td>Propranolol LA</td>
      <td>β<sub>1</sub>, β<sub>2</sub></td>
      <td>0</td>
      <td>80-160mg QD</td>
      <td> </td>
    </tr>
    <tr>
      <td>Timolol</td>
      <td>β<sub>1</sub>, β<sub>2</sub></td>
      <td>0</td>
      <td>10-20mg BID</td>
      <td>PO and Ophthalmic (Glaucoma)</td>
    </tr>
  </tbody>
</table>

<h3 id="ses-1">SEs</h3>

<ul>
  <li>Bronchoconstriction (particularly those with β<sub>2</sub> activity)</li>
  <li>Bradycardia / AV Block</li>
  <li><strong>Difficulty identifying Hypoglycemia</strong></li>
  <li><strong>Withdrawal can cause HTN Crisis</strong></li>
  <li>Fatigue</li>
  <li>Depression</li>
  <li>Nightmares</li>
  <li>Sexual dysfunction</li>
</ul>

<h2 id="catecholamine-depleters">Catecholamine Depleters</h2>

<ul>
  <li>Reserpine
    <ul>
      <li>Blocks VMAT inhibiting vesicular loading</li>
      <li>Lasts for weeks</li>
    </ul>
  </li>
</ul>

<h1 id="cholinergics">Cholinergics</h1>

<h2 id="cholinergic-toxidrome">Cholinergic Toxidrome</h2>

<p><strong>SLUD</strong></p>

<ul>
  <li>Salivation</li>
  <li>Lacrimation</li>
  <li>Urination</li>
  <li>Defecation</li>
  <li>Sweating</li>
  <li>Pupil constriction</li>
  <li>Hallucinations</li>
  <li>Bradycardia</li>
</ul>

<h2 id="direct-cholinergic-agents">Direct Cholinergic Agents</h2>

<ul>
  <li>Acetylcholine</li>
  <li>Carbachol</li>
  <li>Methacholine</li>
  <li>Bethanechol (Muscharinic Agonist)</li>
  <li>Muscarine</li>
  <li>Nicotine</li>
  <li>Pilocarpine (Muscharinic Agonist)</li>
  <li>Varenicline (Partial Nicotinic Agonist)</li>
</ul>

<h2 id="cholinesterase-inhibitors">Cholinesterase Inhibitors</h2>

<ul>
  <li>Reversible
    <ul>
      <li>Edrophonium
        <ul>
          <li>Dx of Myasthenia Gravis (SSx will resolve almost immediately)</li>
        </ul>
      </li>
      <li>Neostigmine</li>
      <li>Pyridostigmine</li>
      <li>Physostigmine
        <ul>
          <li>Anticholinergic antidote</li>
        </ul>
      </li>
      <li>Tacrine</li>
      <li>Donepezil</li>
      <li>Rivastigmine</li>
      <li>Galantamine</li>
      <li>Memantine</li>
    </ul>
  </li>
  <li>Irreversible
    <ul>
      <li>Organophosphates</li>
      <li>Isoflurophate</li>
      <li>Echothiophate</li>
      <li>Sarin</li>
      <li>Soman</li>
      <li>Malathion</li>
      <li>Diazinon</li>
    </ul>
  </li>
</ul>

<h3 id="treatment-of-anticholinesterase-inhibitor-poisoning">Treatment of Anticholinesterase Inhibitor Poisoning</h3>

<ul>
  <li>2-PAM (Pralidoximine, 2-pyridine aldoxime methyl chloride)</li>
  <li>Organophosphate Poisoning IV: 30 mg/kg (Max 2g) then 8-10 mg/kg/hr (Max 650 mg/hr)</li>
  <li>Organophosphate Poisoning IM
    <ul>
      <li>Mild: 600mg IM repeat q15min PRN NTE 1800mg</li>
      <li>Severe: 600mg IM rapid repeat NTE 1800mg</li>
      <li>Persistent: May repeat 1800mg series q1h</li>
    </ul>
  </li>
  <li>Reversible Anticholinesterase Inhibitors: 2-PAM or Anticholinergic agents
    <ul>
      <li>2-PAM: 1-2g IV then 250mg q5min PRN</li>
    </ul>
  </li>
</ul>

<h1 id="anticholinergics">Anticholinergics</h1>

<ul>
  <li>Atropine
    <ul>
      <li>0.5mg: Slight cardiac slowing, some oral dryness, and inhibition of sweating</li>
      <li>1mg: Tachycardia, mild mydriasis, oral dryness</li>
      <li>2mg: Tachycardia / palpitations, mydriasis, blurring of near vision, oral dryness</li>
      <li>5mg: All above SSx marked, difficulty speaking / swallowing, HA, hot / dry skin</li>
      <li>≥ 10mg: All above SSx, iris obliterated, vision very blurry, hallucinations, coma, ataxia</li>
    </ul>
  </li>
  <li>Ipratroprium
    <ul>
      <li>COPD</li>
    </ul>
  </li>
  <li>Scopolamine
    <ul>
      <li>Motion Sickness</li>
      <li>Highest CNS penetration</li>
    </ul>
  </li>
  <li>Homatropine
    <ul>
      <li>Cycloplegia and Mydriasis</li>
    </ul>
  </li>
  <li>Tropicamide
    <ul>
      <li>Cycloplegia and Mydriasis</li>
    </ul>
  </li>
  <li>Benztropine
    <ul>
      <li>PD and EPS</li>
    </ul>
  </li>
  <li>Glycopyrrolate
    <ul>
      <li>GI Disorders (charged, won’t enter CNS)</li>
    </ul>
  </li>
  <li>Propantheline
    <ul>
      <li>GI Disorders (charged, won’t enter CNS)</li>
    </ul>
  </li>
</ul>

<h2 id="paralytics">Paralytics</h2>

<p><strong>DO NOT ADMINISTER A PARALYTIC WITHOUT SUFFICIENT OPIOID ANALGESIA OR SIGNIFICANT SEDATION (Propofol, Ketamine, Etomidate, Volatile Anesthetics, etc)</strong></p>

<ul>
  <li>Succinylcholine
    <ul>
      <li>1-2 mg/kg IV or 4-5 mg/kg IM</li>
      <li>Depolarizing blocker</li>
      <li>Causes hyperkalemia</li>
      <li>Short acting (effect ends in &amp;approx;5 min)</li>
    </ul>
  </li>
  <li>Non-Depolarizing
    <ul>
      <li>Vecuronium
        <ul>
          <li>0.1 mg/kg</li>
          <li>Lasts 30-60min</li>
        </ul>
      </li>
      <li>Pancuronium
        <ul>
          <li>0.1 mg/kg</li>
          <li>45-90 min</li>
        </ul>
      </li>
      <li>Rocuronium
        <ul>
          <li>0.8-1 mg/kg (30-45 min)</li>
        </ul>
      </li>
    </ul>
  </li>
</ul>

  </div>

</div>

<div class="credits">
  <p>Author: Corbin Cox <br>
  Created: 2018-2-8 <br>
  Last Updated: 2018-6-24</p>
</div>

<footer class="footer menus">
  <nav>
    <ul class="footer-links">
      <li><a href="/peripheral_brain/home.html">Home</a></li>
      <li><a href="/peripheral_brain/index.html">Disclaimer</a></li>
    </ul>
    <!-- <a href="/peripheral_brain/home.html"><img src="/peripheral_brain/images/logo_1000x1000.png" alt="Logo"> -->
  </nav>
</footer>


</body>
</html>
